HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

References

• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-057826667886
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterizing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi:10.1111/j.1742-1241.2011.02799.x21995694
   PubMed Web of Science ®Google Scholar
• AIOM, CCM, AIRTUM. I numeri del cancro 2017. [The number of cancer in Italy 2017]. Available from: http://www.registri-tumori.it/PDF/AIOM2017/2017_numeri_del_cancro.pdf. Accessed September 20, 2018.
   Google Scholar
• Halabi S, Lin CY, Kelly WK, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. JCO. 2014;32(7):671–677. doi:10.1200/JCO.2013.52.3696
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Stat facts: prostate cancer. 2018 Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed February 15, 2019.
   Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. NEJM. 2004;351(15):1513–1520. doi:10.1056/NEJMcp04195615470214
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM. 2004;351(15):1502–1512. doi:10.1056/NEJMoa04072015470213
   PubMed Web of Science ®Google Scholar
• Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16(6):e279–e292. doi:10.1016/S1470-2045(15)70033-126065613
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second – generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790. doi:10.1126/science.116817519359544
   PubMed Web of Science ®Google Scholar
• Lorente D, Fizazi K, Sweeney C, de Bono JS. Optimal treatment sequence for metastatic castration – resistant prostate cancer. Eur Urol Focus. 2016;2(5):488–498. doi:10.1016/j.euf.2016.10.00828723514
   PubMedGoogle Scholar
• Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405. doi:10.1136/bmj.i440527754846
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017;73(2):178–211.28655541
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, Al E. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160. doi:10.1016/S1470-2045(14)71205-725601341
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf D, et al Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–154. doi:10.1016/j.eururo.2016.07.03227477525
   PubMed Web of Science ®Google Scholar
• Clore JN, Thurby-Hay L. Glucocorticoid – induced hyperglycemia. Endocr Pract. 2009;15:469–474. doi:10.4158/EP08331.RAR19454391
   PubMed Web of Science ®Google Scholar
• Bonomio M. Iperglicemia da steroidi: meccanismi e trattamento. [Steroid hyperglycemia: mechanisms and treatment]. G IT Diabetol Metab. 2015;35:8–15. Italian.
   Google Scholar
• De Micheli A. Il diabete steroideo: inquadramento e gestione. [Steroid diabetes: classification and management]. G Ital Nefrol. 2016;33:S68 Italian.
   Google Scholar
• Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229. doi:10.1016/j.clinthera.2017.09.01129055500
   PubMed Web of Science ®Google Scholar
• Massoudi M, Balk M, Yang H, et al. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017;20(2):121–128. doi:10.1080/13696998.2016.122967027570999
   PubMed Web of Science ®Google Scholar
• Restelli U, Ceresoli GL, Croce D, et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Manag Res. 2017;7(9):789–800. doi:10.2147/CMAR.S148323
   Web of Science ®Google Scholar
• Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–258. doi:10.1017/S026646230808034318601792
   PubMed Web of Science ®Google Scholar
• EUNetHTA. The HTA Core Model, Version 3.0., 4 2016 Available from: http://eunethta.eu/sites/5026.fedimbo.belgium.be/files/HTACoreModel3.0.pdf. Accessed September 20, 2018.
   Google Scholar
• Thokala P, Duenas A. Multicriteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–1181. doi:10.1016/j.jval.2012.06.01523244821
   PubMed Web of Science ®Google Scholar
• Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making — an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13. doi:10.1016/j.jval.2015.12.00326797229
   PubMed Web of Science ®Google Scholar
• Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Ann Symp Proc. 2006;359–363.
   PubMedGoogle Scholar
• Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16. doi:10.1186/1472-6947-7-1617573961
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. The prisma group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al., The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed February 15, 2019.
   Google Scholar
• Foglia E, Lettieri E, Ferrario L, et al. Technology assessment in hospitals: lessons learned from an empirical experiment. Int J Technol Assess Health Care. 2017;33(2):288–296. doi:10.1017/S026646231700035628578752
   PubMedGoogle Scholar
• Quinn Patton M. Qualitative Research & Evaluation Methods. 3rd ed. Thousand Oaks, CA: Sage publications; 2002.
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 17 marzo 2016 Regime di rimborsabilità e prezzo di vendita a seguito di nuove indicazioni terapeutiche del medicinale per uso umano “Xtandi”. (Determina n. 405/2016). Gazzetta n.81 del 7 aprile 2016). [Italian Medicines Agency. Resolution 17 March 2016. Reimbursement regime and selling price of the medicine “Xtandi”. (Resolution n. 405/2016) (Gazzetta n.81 – 7 April 2016). Available from: http://www.gazzettaufficiale.it/eli/id/2016/04/07/16A02656/sg.
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 4 settembre 2014 Regime di rimborsabilità e prezzo di vendita a seguito di nuove indicazioni terapeutiche del medicinale per uso umano “Zytiga”. (Determina n. 927/2014). (Gazzetta n.214 del 15 settembre 2014). [Italian Medicines Agency. Resolution 4 September 2014. Reimbursement regime and selling price of the medicine “Xtandi”. (Resolution n. 927/2014) (Gazzetta n.214 – 15 September 2014). Available from: http://www.gazzettaufficiale.it/eli/id/2014/09/15/14A07107/sg.
   Google Scholar
• Agenzia Italiana del Farmaco. “Riassunto delle Caratteristiche del Prodotto: abiraterone acetato”, Documento reso disponibile da AIFA nel 2016.
   Google Scholar
• Agenzia Italiana del Farmaco. “Riassunto delle Caratteristiche del Prodotto: enzalutamide”, Documento reso disponibile da AIFA nel 2016.
   Google Scholar
• Porter M. What is value in health care? N Engl J Med. 2010;363(26):2477–2481. doi:10.1056/NEJMp101102421142528
   PubMed Web of Science ®Google Scholar
• Porter ME, Teisberg EO. Redefining Health Care: Creating Value-Based Competition on Results. Boston: Harvard Business School Press; 2006.
   Google Scholar
• Union for International Cancer Control’s (UICC). New global cancer data: GLOBOCAN 2018 Available from: https://www.uicc.org/new-global-cancer-data-globocan-2018. Accessed February 15, 2018.
   Google Scholar
• Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic prostate cancer incidence and prostate – specific antigen testing: new insights from European randomized study of screening for prostate cancer. Eur Urol. 2015;68(5):885–890. doi:10.1016/j.eururo.2015.02.04225791513
   PubMedGoogle Scholar
• Carteni G, Pappagallo G. Carcinoma della prostata resistente alla castrazione in Italia: un unmet in via di risoluzione. [Castrate Resistant Prostate CANCER IN Italy: an unmet medical need about to be solved]. Ital J Public Health. 2011;8(Suppl 4):S3–S8. Italian.
   Google Scholar
• Marteau F, Gimonet G, Gabriel S, Dinet J, Flinois A, LE Cleac’h JY. Epidemiology of patients with metastatic castrate resistant prostate cancer in Europe and Australia. Value Health. 2017;17(7):a619. doi:10.1016/j.jval.2014.08.2188
   Web of Science ®Google Scholar
• Sternberg C, De Bono J, Chi K, et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. J Clin Oncol. 2013;31(Suppl. 6):abstract 16. doi:10.1200/JCO.2013.49.0219
   Web of Science ®Google Scholar
• Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, Tringali M. Implementation of Eunethta core model® in Lombardia: the VTS framework. Int J Technol Assess Health Care. 2014;30(01):105–112. doi:10.1017/S026646231300063924451150
   PubMedGoogle Scholar
• Loriot Y, Miller K, Sternberg CN, et al Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509–521. doi:10.1016/S1470-2045(15)70113-025888263
   PubMed Web of Science ®Google Scholar
• Gold MR. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
   Google Scholar
• Bui C, O’Day K, Flanders S, et al. Budget impact analysis of enzalutamide for the treatment of metastatic castration-resistant prostate cancer from a US payer perspective. Value Health. 2015;18(3):A196. doi:10.1016/j.jval.2015.03.1135
   Web of Science ®Google Scholar
• Bui C, O’Day K, Flanders S, et al. Budget impact of enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22(2):163–170. doi:10.18553/jmcp.2016.22.2.16327015255
   PubMed Web of Science ®Google Scholar
• Pollard ME, Moskowitz AJ, Diefenbach MA, Hall SJ. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017;4(1):37–43. doi:10.1016/j.ajur.2016.11.00529264205
   PubMed Web of Science ®Google Scholar
• Pilon D, Queener M, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19:777–784. doi:10.3111/13696998.2016.117304227031255
   PubMed Web of Science ®Google Scholar
• Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18(2):155–166.6851197
   PubMed Web of Science ®Google Scholar
• Pagano G, Cavallo-Perin P, Cassader M, et al An in vivo and in vitro study of the mechanism of prednisone – induced insulin resistance in healthy subjects. J Clin Invest. 1983;72(15):1814–1820. doi:10.1172/JCI1111416355186
   PubMedGoogle Scholar
• Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid – induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717–720.12220369
   PubMed Web of Science ®Google Scholar
• Cella D, Ivanescu C, Holmstrom S, et al Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol. 2015;26(1):179–185. doi:10.1093/annonc/mdv38325361992
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, de Bono JS, et al Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825. doi:10.1016/j.eururo.2014.01.00324647231
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.9250266
   PubMed Web of Science ®Google Scholar
• Pollack A. New drug for prostate cancer gets F.D.A. Nod. The New York Times. 2012 The New York Times Company, New York. doi:10.1094/PDIS-11-11-0999-PDN
   Google Scholar